Hyreb-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, indicated for the treatment of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief. The synergistic action of these two agents addresses both the underlying acid hypersecretion and impaired gastric motility, offering comprehensive symptom control. Hyreb-DSR is typically administered orally once daily before meals, with dosage adjustments based on clinical response and tolerability. It is contraindicated in patients with known hypersensitivity to either component, and caution is advised in individuals with hepatic impairment or prolactin-secreting pituitary tumors. Common adverse effects may include headache, dry mouth, abdominal cramps, and diarrhea. Patients should consult healthcare professionals prior to use, especially if pregnant, breastfeeding, or on concurrent medications to avoid potential drug interactions. Hyreb-DSR Capsule provides an effective therapeutic option for managing acid-related gastrointestinal conditions with improved patient compliance.